Cover Image
Market Research Report

Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends

Published by BIOINFORMANT WORLDWIDE, LLC Product code 691737
Published Content info 195 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends
Published: December 10, 2019 Content info: 195 Pages
Description

CAR-T cell therapy is a remarkably promising treatment for cancer patients. This emerging treatment is one of the biggest breakthroughs since the introduction of chemotherapy. CAR-T is a type of immunotherapy where doctors collect immune cells from a patient, modify them in a laboratory, and provide them the power to easily recognize and kill cancer cells and infuse them back into the patient. The infused cells get multiplied and stay in the body as "living drugs."

In the past, significant successes were made possible by chemotherapy and radiation by killing cancer cells. However, the effects were not permanent. Now, CAR-T cells are providing a compelling alternative. T-cells form the backbone of CAR-T cell therapy. T-cells are the workhorses of the immune system and they play a key role in directing the immune response and killing cells infected by pathogens.

The purpose of this report is to describe the current status of chimeric antigen receptor T-cells (CAR-T cells), the related patent landscape, funding, deals, research, applications, technologies, the details of the two marketed CAR-T cell products, and the ongoing and late stage clinical trials.

The widespread research activities, worldwide clinical trials and approved treatments (Kymriah and Yescarta) have created a robust CAR-T cell therapy market. This billion dollar market size and its strong growth would not be possible without the remarkable efficacy of Kymriah and Yescarta in treating several types of blood cancers. CAR-T cell therapy has swept the biotech industry by storm, attracting new market participants at a rapid pace.

The main objectives of this report are to provide the reader with the following details:

  • Currently available CAR-T cell therapy products and the treatable indications.
  • The late-stage CAR-T product candidates.
  • Number of clinical trials focusing on CAR-T cells targeting solid tumors.
  • New designs and concepts of CAR-T cells.
  • Funding for CAR-T cell-based research.
  • Key patents filed in recent years.
  • Number of clinical trials involving CAR-T cells.
  • Advantages of CAR-T cell therapy over other immunotherapies and chemotherapies.
  • Number of companies contributing to CAR-T cell therapy market and their product candidates.

Key questions answered in this report are:

  • What are CAR-T cells?
  • What are the various indications for CAR-T cell therapies?
  • Which cancers are treated by the currently available Kymriah and Yescarta?
  • What is the timeline for the development of CAR-T cell therapy?
  • How are autologous and allogeneic CAR-T cells manufactured?
  • What is the structure of a CAR-T cell?
  • What are first generation, second generation, third generation and fourth generation CAR-T cells?
  • What is the mechanism of action of CAR-T cells?
  • What is the future of CAR-T cell therapy with the arrival of new models and concepts?
  • What are the target antigens in CAR-T cell therapy?
  • What are the target antigens in solid tumors?
  • What is the price structure of CAR-T products?
  • How many medical facilities are currently offering CAR-T cell therapy?
  • How many patent applications have been filed?
  • How many deals, partnerships and collaborations have been signed in recent years?
  • What is the funding landscape in the CAR-T space?
  • How many clinical trials are actively conducted in the CAR-T space?
  • Which clinical trials are run by biotech companies?
  • Which clinical trials are conducted by academicia?
  • How do Tisagenlecleucel (Kymriah) and Axicabtagene ciloleucel (Yescarta) bring about the death of cancer cells in hematological malignancies?
  • What is the total cost of treating a patient with CAR-T cell therapy?
  • How much relief is provided by insurance companies to the patients?
  • What are the strengths and weaknesses of the CAR-T cell therapy industry?
  • What is the global market for CAR-T cells?
  • What is the global market for CAR-T cells by geography?
  • What is the market for CAR-T cells by target antigen?
  • How many companies are involved in developing CAR-T cell therapies and what product/technologies are they developing?
Table of Contents

Table of Contents

1 REPORT OVERVIEW

  • 1.1Statement of the Report
  • 1.2Executive Summary
  • 1.3INTRODUCTION

2 HISTORY OF CAR-T CELL THERAPY

  • 2.1Timeline of CAR-T Cell Therapy Development

3 CAR-T MANUFACTURING PROCESSES

  • 3.1Manufacturing Autologous CAR-T Cells
  • 3.2T-CellSource
  • 3.3T-Cell Activation
    • 3.3.1 Beads-Based T-Cell Activation
    • 3.3.2 Antibody-Coated Magnetic Beads
    • 3.3.3 Antibody-Coated Nanobeads
    • 3.3.4 Expamer Technology
    • 3.3.5 Activation with Anti-CD3 Antibodies
  • 3.4Genetic Modification of T-Cells
  • 3.5Expansion of CAR-T Cells
    • 3.5.1 Expansion of CAR-T Cells using GE Bioreactors
    • 3.5.2 Expansion of CAR-T Cells using G-Rex Bioreactors
    • 3.5.3 Expansion of CAR-T Cells using Prodigy
    • 3.5.4 Expansion of CAR-T Cells through Recursive AAPC Stimulation
  • 3.6Clinical CAR-T Cell Manufacturing Quality Checkpoints
    • 3.6.1 Qualification of Manufacturing Facilities
    • 3.6.2 Qualification of Ancillary Components
    • 3.6.3 Qualification of Manufacturing Process
  • 3.7In-Process Testing and Release Testing of Cellular Products
  • 3.8Allogeneic CAR-T Cells

4 STRUCTURE OF A CAR-T CELL

  • 4.1First Generation CAR-T Cells
  • 4.2Second Generation CAR-T Cells
  • 4.3Third Generation CAR-T Cells
  • 4.4Fourth Generation CAR-T Cells
  • 4.5Mechanism of Action
  • 4.6New CAR Models and Concepts
    • 4.6.1 Truck CAR
    • 4.6.2 Universal CAR
    • 4.6.3 Self-driving CAR
    • 4.6.4 Armored CAR
    • 4.6.5 Self-destruct CAR
    • 4.6.6 Conditional CAR
    • 4.6.7 TanCAR
    • 4.6.8 Dual CAR
    • 4.6.9 Safety CAR )sCAR)
  • 4.7Basic Components of CAR
    • 4.7.1 Common Deigns of CAR-T Constructs
      • 4.7.1.1 Single Chain Fv Fragments (scFv)
      • 4.7.1.2 4-1BB, CD28, OX40, FcεRIγ and CD3ξ
      • 4.7.1.3 Vectors for Transfection

5 NUMBER OF CAR-T COMPANIES, THEIR RECENT ACTIVITIES

  • 5.1Geographical Distribution of CAR-T Cell Therapeutic Companies
  • 5.2Immunocellular Therapy Companies by Cell Type
  • 5.3Market Leaders in CAR-T Cell Therapy and their Recent Activities
    • 5.3.1 AbbVie
    • 5.3.2 Allogene Therapeutics
    • 5.3.3 Amgen
    • 5.3.4 Agios Pharmaceutical
    • 5.3.5 Atara Biotherapeutics
    • 5.3.6 Autolus Limited
    • 5.3.7 Bellicum Pharmaceuticals
    • 5.3.8 bluebird bio
    • 5.3.9 Calibr
    • 5.3.10 Carina Biotech
    • 5.3.11 CARsgen Therapeutics
    • 5.3.12 Celgene Corporation
    • 5.3.13 Cellectis
    • 5.3.14 Cell Medica
    • 5.3.15 Cell Design Labs
    • 5.3.16 Celularity
    • 5.3.17 Celyad
    • 5.3.18 Fate Therapeutics
    • 5.3.19 Fortress Bio
    • 5.3.20 Gilead Sciences
    • 5.3.21 Janssen Biotech
    • 5.3.22 Juno Therapeutics
    • 5.3.23 JW Therapeutics
    • 5.3.24 Kite Pharma
    • 5.3.25 Medisix Therapeutics
    • 5.3.26 Mustang Bio
    • 5.3.27 Nanjing Legend Biotech
    • 5.3.28 Novartis
    • 5.3.29 Pfizer
    • 5.3.30 Precision Biosciences
    • 5.3.31 Posedia Therapeutics
    • 5.3.32 Shire
    • 5.3.33 Sorrento Therapeutics
    • 5.3.34 Ziopharm

6 TUMOR-ASSOCIATED TARGET ANTIGENS

  • 6.1Antigens on Solid Tumors
    • 6.1.1 Epidermal Growth Factor Receptor (EGFR)
    • 6.1.2 Epidermal Growth Factor Receptor Variant III (EGFRvIII)
    • 6.1.3 Human Epidermal Growth Factor Receptor-2 (HER2)
    • 6.1.4 Mesothelin (MSLN)
    • 6.1.5 Prostate-Specific Membrane Antigen (PSMA)
    • 6.1.6 Disialoganglioside 2 (GD2)
    • 6.1.7 Interleukin-13Rα2 (IL13Rα2)
    • 6.1.8 Glypican-3 (GPC3)
    • 6.1.9 Carbonic Anhydrase IX (CAIX)
    • 6.1.10 L1 Cell Adhesion Molecule (L1-CAM)
    • 6.1.11 Cancer Antigen 125 (CA125) (MUC16)
    • 6.1.12 Prominin-1 (CD133)
    • 6.1.13 Fibroblast Protein-α (FAP-α)
    • 6.1.14 Cancer/Testis Antigen 1B (CTAG1B)
    • 6.1.15 Mucin 1 (MUC1)
    • 6.1.16 Folate Receptor-α (FR-α)
  • 6.2CAR-T Targets in Hematologic Malignancies
    • 6.2.1 CD19
    • 6.2.2 CD20
    • 6.2.3 CD22
    • 6.2.4 ROR1
    • 6.2.5 CD30
    • 6.2.6 CD138
    • 6.2.7 CD123
    • 6.2.8 NKG2D-L
    • 6.2.9 BCMA
    • 6.2.10 CD174
  • 6.3CAR-T Cell Trials Targeting CD19
    • 6.3.1 Positive CR Rates in CD19 Targeted Studies in Hematological Malignancies
    • 6.3.2 Outcome of CAR-T Cell Therapy Trials Targeting Antigens other than CD19
    • 6.3.3 Targets other than CD19 in Hematological Cancers
    • 6.3.4 CD30 vs. BCMA Targets for Multiple Myeloma
  • 6.4CAR-T Cell Therapy for Solid Tumors
    • 6.4.1 CAR-T Cell Targets in Solid Malignancies

7 TARGET DISEASES FOR CAR-T CELL THERAPY

  • 7.1Acute Lymphoblastic Leukemia (ALL)
  • 7.2Chronic lymphocytic leukemia (CLL)
  • 7.3Non-Hodgkin lymphoma
  • 7.4Acute myeloid leukemia (AML)
  • 7.5Neuroblastoma
  • 7.6Multiple myeloma (MM)

8 PRICING AND PAYMENT MODELS FOR CAR-T THERAPIES

  • 8.1Controversies over CAR-T Pricing
  • 8.2Hospital Mark-up Costs for Kymriah and Yescarta
  • 8.3Cost Effectiveness of Tisagenlecleucel and Axicabtagene
  • 8.4Value-Based Price Benchmarks
  • 8.5Unit Prices Needed to Reach Cost-Effectiveness Thresholds
  • 8.6Alternate Payment Strategies

9 MEDICAL FACILITIES OFFERING CAR-T THERAPIES

  • 9.1CAR-T Recommended in Europe
  • 9.2CAR-T Cell Therapy in Chinese Hospital
  • 9.3Canada Joins the CAR-T Club

10 CAR-T THERAPY PATENT LANDSCAPE

  • 10.1Number of CAR-T Cell Patents, 2013-2018
  • 10.2CAR-T Patent Types
  • 10.3A Brief Snapshot of CAR-T Patent Landscape
    • 10.3.1 Patents for Anti-CD19 CAR-T
    • 10.3.2 Patents for Anti-BCMA CAR-T
    • 10.3.3 Patents for Regulatable CAR-T
    • 10.3.4 Patents for CAR-T for Solid Tumors
    • 10.4Major CAR-T Patent Applicants

11. DEALS, FUNDINGS, PARTNERSHIPS AND COLLABORATIONS

  • 11.1Funding for CAR-T
  • 11.2CAR-T Deals
  • 11.3Initial Public Offering (IPO)
  • 11.4Key CAR-T Technology Deals
    • 11.4.1 Deal between Juno Therapeutics and Eureka for a Fully Human ScFv Binding Domain
    • 11.4.2 Acquisition of Stage Cell Therapeutics by Juno Therapeutics
    • 11.4.3 Collaboration between Juno Therapeutics and Editas Medicine
    • 11.4.5 Kite and Alpine in Research and License Agreement
    • 11.4.6 Johnson & Johnson Gets PiggyBac Technology from Transposagen
    • 11.4.7 Johnson & Johnson and Posedia in a Technology Deal
    • 11.4.8 Partnership between Baxalta and Precision Biosciences
    • 11.4.9 Novartis, Intellia and Caribou
    • 11.4.10 Trends in Oncology Licensing, Joint Venture and Research Deals

12 THE LANDSCAPE OF CAR-T CELL THERAPY CLINICAL TRIALS

  • 12.1The Surge in Number of CAR-T Clinical Trials
  • 12.2Percentage (%) of Total CAR-T Clinical Trials by Target
  • 12.3Research Focus on CAR-T Trials by Indication
  • 12.4Clinical Trials using CAR-T Cells by Country as of 2018
  • 12.5CAR-T Clinical Trials to Watch
  • 12.6CAR-T Projects with Commercial Licensees
  • 12.7Clinical CAR-T Constructs with Sole Involvement from Academicia
  • 12.8Anti-CD19 CAR-T Studies
  • 12.9CAR-T Studies in Multiple Myeloma and Acute Myeloid Leukemia
  • 12.10CAR-T Cell Therapy for Solid Tumors
  • 12.11Studies of CAR-T Projects Transfected using mRNA Electroporation
  • 12.12CAR-T Projects Incorporating Suicide Genes
  • 12.13Early Stage CAR-T Assets
  • 12.14Anti-CD22 CAR-T Projects
  • 12.15Cytokine Release Syndrome (CRS) with CART19 Therapy
  • 12.16CAR-T Therapy Pipeline Distribution by Indication
  • 12.17CAR-T Therapy Pipeline Distribution by Target Antigen
  • 12.18Distribution of CAR-T Clinical Trials in China
    • 12.18.1 CD19-Directed CAR-T Clinical Trials in China
    • 12.18.2 Chinese Trials Targeting Non-CD19 Antigens
    • 12.18.3 Chinese Trials on Solid Tumors
    • 12.18.4 Chinese Trials Using Fourth Generation CAR Constructs
    • 12.18.5 Clinical Stage CAR-T Projects in China

13 CAR-T CELL PRODUCTS IN THE MARKET

  • 13.1Tisagenlecleucel (Kymriah)
    • 13.1.1 Evidences Supporting Effectiveness of Tisagenlecleucel (Kymriah)
    • 13.1.2 Medical Necessities for Tisagenlecleucel (Kymriah)
    • 13.1.3 Overall Remission Rates in Patients Treated with Kymriah
    • 13.1.4 Overall Event-Free Survival Rate with Tisagenlecleucel (Kymriah)
    • 13.1.5 Key Adverse Events in ELIANA Trial
    • 13.1.6 Key Adverse Events in JULIET Trial
    • 13.1.7 Budget Impact for Tisagenlecleucel
    • 13.1.8 Overall Adverse Events with Tisagenlecleucel
    • 13.1.9 Per-Patient Potential Budget Impact of Tisagenlecleucel
  • 13.2Axicabtagene Ciloleucel (Yescarta)
    • 13.2.1 Evidences to Support the Effectiveness of Axicabtagene Ciloleucel
    • 13.2.2 Medical Necessities for Axicabtagene Ciloleucel (Yescarta)
    • 13.2.3 Clinical Benefits of Axicabtagene Ciloleucel (Yescarta)
    • 13.2.4 Objective Response Rates (ORR) for Axicabtagene Ciloleucel
    • 13.2.5 CRR for Axicabtagene Ciloleucel
    • 13.2.6 Adverse Events in ZUMA-Trial
    • 13.2.7 Base-Case Results
    • 13.2.8 Value-Based Benchmark Prices
    • 13.2.9 Per-Patient Budget Impact of Axicabtagene Ciloleucel
    • 13.2.10 Unit Cost for Healthcare Utilization in CAR-T Therapy
    • 13.2.10.1 Costs Associated with Adverse Events

14 INSURANCE COVERAGE FOR CAR-T THERAPY

  • 14.2Coverage Policies for Tisagenlecleucel - B-ALL Patients
  • 14.2Coverage for Stem Cell Transplantation (SCT) - B-Cell ALL Patients
  • 14.3Coverage for Axicabtagene Ciloleucel - B-Cell NHL Patients
  • 14.4Coverage for Stem Cell Plantation (SCT) in B-Cell NHL Patients
  • 14.5Insurance Coverage by Medicare and Medicaid

15 COMMERCIAL THREATS FOR CAR-T INDUSTRY

  • 15.1Competition in a Narrow Field
  • 15.2Competition from other Technologies
  • 15.3Threat from TCRs
  • 15.4Threat of Litigation

16 CHALLENGES TO OVERCOME

  • 16.1Lack of Persistence
  • 16.2Inadequate Activation
  • 16.3Transfection Method
  • 16.4Humanized Binding Domains
  • 16.5Antigen Escape
  • 16.6Lineage Switching
  • 16.7Lack of Safety
  • 16.8Benefits of CAR-T Cell Therapy
  • 16.9CAR-T Cell Therapy: Only the Beginning of the Story
  • 16.10A New Standard

17 MARKET ANALYSIS

  • 17.1Global Market for CAR-T Therapy by Geography
  • 17.2Global Market for CAR-T Therapy by Country
  • 17.3Global Market for CAR-T Cell Therapy by Targeted Antigens
  • 17.4Competitive Landscape

18 COMPANY PROFILES

  • 18.1AbbVie Inc.
    • 18.1.1 Collaboration with Calibr
  • 18.2Adaptimmune Therapeutics PLC
    • 18.2.1 Pipeline
  • 18.3Amgen, Inc.
    • 18.3.1 Amgen's Collaboration with Kite Pharma
    • 18.3.2 Amgen's Collaboration with MD Anderson Cancer Center
  • 18.4Atara Biotherapeutics, Inc.
    • 18.4.1 Technology
    • 18.4.2 Atara tab-cel™
    • 18.4.3 Atara ATA188
    • 18.4.4 Atara ATA230
  • 18.5Aurora Biopharma, Inc.
    • 18.5.1 CAR-T for Glioblastoma
  • 18.6Autolus Therapeutics PLC
    • 18.6.1 Technology
  • 18.7Bellicum Pharmaceuticals, Inc.
    • 18.7.1 GoCAR Technology
    • 18.7.2 BPX-501
    • 18.7.3 BPX-601
    • 18.7.4 BPX-701
  • 18.8BioAtla LLC
    • 18.8.1 Conditionally Active Biologics (CABs)
    • 18.8.2 Agreement with Pfizer
    • 18.8.3 Agreement with Sinobioway
  • 18.9bluebird bio
    • 18.9.1 Technology
  • 18.10Carina Biotech
    • 18.10.1 Technology
  • 18.11CARsgen Therapeutics, Ltd.
  • 18.12CARTherics
  • 18.13Cellectis
    • 18.13.1 Products
  • 18.14Celularity
  • 18.15Celyad SA
  • 18.16Creative Biolabs
  • 18.17DiaCarta, Inc.
    • 18.17.1 Personalized CAR-T Immunotherapy Platform
  • 18.18Endocyte, Inc.
    • 18.18.1 LU-PSMA-617
    • 18.18.2 Adaptor-Controlled CAR-T Therapy
  • 18.19F1 Oncology, Inc.
    • 18.19.1 Conditionally Active Biologics (CAB) Technology
  • 18.20Fate Therapeutics Inc.
  • 18.21Humanigen, Inc.
    • 18.21.1 Ifabotuzumab
  • 18.22Immune Therapeutics, Inc.
    • 18.22.1 CAR-T from Immune Therapeutics
  • 18.23Intrexon, Corp.
  • 18.24Juno Therapeutics, Inc.
  • 18.25Kite Pharma, Inc.
    • 18.25.1 Product
      • 18.25.1.1 Yescarta (Axicabtagene ciloleucel)
  • 18.26Lion TCR Pte Ltd.
    • 18.26.1 Technology
    • 18.26.1.2 Virus-Related Cancers
  • 18.27MaxCyte, Inc.
    • 18.27.1 CARMA Platform
  • 18.28Mesoblast, Ltd.
    • 18.28.1 Partnership with Cartherics
  • 18.29Minerva Biotechnologies Corp.
    • 18.29.1 Solid Tumor Cancer Portfolio
    • 18.29.2 Antibody Therapeutic for MUC1* Positive Cancers
    • 18.29.3 Anti-Metastasis Antibody
    • 18.29.4 MUC1*
  • 18.30Mustang Bio, Inc.
  • 18.31Novartis AG
    • 18.31.1 Kymriah (Tisagenlecleucel)
  • 18.32Oxford BioMedica PLC.
    • 18.32.1 LentiVector Platform
  • 18.33PeproMene Bio Inc.
    • 18.33.1 BAFFR R CAR-Cell
  • 18.34Pfizer, Inc.
    • 18.34.1 Asset Contribution Agreement with Allogene Therapeutics
  • 18.35Posedia Therapeutics Inc.
  • 18.36Precision Biosciences, Inc.
    • 18.36.1 Precision Biosciences' Cancer Immunotherapy
  • 18.37ProMab Biotechnologies Inc.
  • 18.38Servier Oncology
  • 18.39Sorrento Therapeutics, Inc.
  • 18.40TC Biopharm Ltd.
    • 18.40.1 ImmuniCAR
    • 18.40.2 OmniCAR
    • 18.40.3 OmnImmune
  • 18.41Tessa Therapeutics Pte Ltd.
    • 18.41.1 TT10 EBVSTs
    • 18.41.2 TT12 Armored HPVSTs
    • 18.41.3 TT14 GPC3-CAR VSTs
    • 18.41.4 TT16 HER2-CAR VSTs
  • 18.42TILT Biotherapeutics Ltd.
    • 18.42.1 Technology
  • 18.43Tmunity Therapeutics Inc.
    • 18.43.1 Technology
  • 18.44TrakCel Ltd.
  • 18.45Xyphos
    • 18.45.1 ConvertibleCAR Technology
  • 18.46ZIOPHARM Oncology, Inc.
    • 18.46.1 IL-12 Platform
    • 18.46.2 Sleeping Beauty

INDEX OF FIGURES

  • FIGURE 1.1: Diagram of the Binding of CAR-T with Antigen of Malignant Cell
  • FIGURE 3.1: Stages from Apheresis to Patient Administration of CAR-T Cells
  • FIGURE 3.2: The Process of CAR-T Cell Manufacturing
  • FIGURE 4.1: Building a CAR-T Cell and its Binding to Tumor Antigen
  • FIGURE 4.2: First Generation CAR-T Cells
  • FIGURE 4.3: Second Generation CAR-T Cells
  • FIGURE 4.4: Third Generation CAR-T Cells
  • FIGURE 4.5: Fourth Generation CAR-T Cells
  • FIGURE 4.6: Recognition and Killing of Tumor Cell by CAR-T Cell
  • FIGURE 4.7: New CAR Models and Concepts
  • FIGURE 4.8: Components of a Chimeric Antigen Receptor
  • FIGURE 4.9: Schematic Representation of scFv Fragment
  • FIGURE 5.1: Global Distribution of CAR-T Cell Therapeutic Companies
  • FIGURE 5.2: Number of Immunocellular Therapy Companies by Cell Type
  • FIGURE 6.1: Percent (%) Share of CAR-T Cell Trials Targeting CD19
  • FIGURE 6.2: Outcome of CAR-T Cell Therapy Trials in Liquid Malignancies, Targeting CD19
  • FIGURE 6.3: Outcome of CAR-T Cell Therapy Trials in Liquid Malignancies, Except CD19
  • FIGURE 6.4: Most Frequent CAR-T Cell Targets in Liquid Malignancies (Except CD19)
  • FIGURE 6.5: Trend in Number of CAR-T Cell Therapy Clinical Trials: CD30 vs. BCMA
  • FIGURE 6.6: Clinical Outcome of CAR-T Cell Therapy Trials in Solid Malignancies
  • FIGURE 6.7: Most Frequent CAR-T Cell Targets in Solid Malignancies
  • FIGURE 10.1: Number of CAR-T Cell Patents, 2013-2018
  • FIGURE 10.2: Major CAR-T Patent Applicants
  • FIGURE 11.1: Licensing, Joint Venture and Research Only Oncology Deals from 2013-2017
  • FIGURE 12.1: Number of Initiated CAR-T Cell Therapy Clinical Trials, 2007-2017
  • FIGURE 12.2: Percentage (%) of Total CAR-T Clinical Trials by Target
  • FIGURE 12.3: Research Focus on CAR-T Trials by Indication
  • FIGURE 12.4: A Model Showing Engineered CD19-CAR-T Cell Targeting CD19 Antigen on the Malignant Cell
  • FIGURE 12.5: CAR-T Cells Targeting Solid Tumor Antigen
  • FIGURE 12.6: CAR-T Therapy Pipeline Distribution by Indication
  • FIGURE 12.7: CAR-T Therapy Pipeline Distribution by Target Antigen
  • FIGURE 17.1: Global Market for CAR-T Cell Therapies, 2018-2024
  • FIGURE 17.2: Global Market for CAR-T Therapy by Geography, 2024
  • FIGURE 17.3: Global Market for CAR-T Therapy by Country, 2024
  • FIGURE 17.4: Global Market for CAR-T Cell Therapies by Targeted Antigen, 2018

INDEX OF FIGURES

  • FIGURE 1.1: Diagrammatic Representation of the Binding of CAR-T with Antigen of Malignant Cell
  • FIGURE 3.1: Stages from Apheresis to Patient Administration of CAR-T Cells
  • FIGURE 3.2: The Process of CAR-T Cell Manufacturing
  • FIGURE 4.1: Building a CAR-T Cell and its Binding to Tumor Antigen
  • FIGURE 4.2: First Generation CAR-T Cells
  • FIGURE 4.3: Second Generation CAR-T Cells
  • FIGURE 4.4: Third Generation CAR-T Cells
  • FIGURE 4.5: Fourth Generation CAR-T Cells
  • FIGURE 4.6: Recognition and Killing of Tumor Cell by CAR-T Cell
  • FIGURE 4.7: New CAR Models and Concepts
  • FIGURE 4.8: Components of a Chimeric Antigen Receptor
  • FIGURE 4.9: Schematic Representation of scFv Fragment
  • FIGURE 5.1: Global Distribution of CAR-T Cell Therapeutic Companies
  • FIGURE 5.2: Number of Immunocellular Therapy Companies by Cell Type
  • FIGURE 6.1: Percent (%) Share of CAR-T Cell Trials Targeting CD19
  • FIGURE 6.2: Outcome of CAR-T Cell Therapy Trials in Liquid Malignancies, Targeting CD19
  • FIGURE 6.3: Outcome of CAR-T Cell Therapy Trials in Liquid Malignancies, Except CD19
  • FIGURE 6.4: Most Frequent CAR-T Cell Targets in Liquid Malignancies (Except CD19)
  • FIGURE 6.5: Trend in Number of CAR-T Cell Therapy Clinical Trials: CD30 vs. BCMA
  • FIGURE 6.6: Clinical Outcome of CAR-T Cell Therapy Trials in Solid Malignancies
  • FIGURE 6.7: Most Frequent CAR-T Cell Targets in Solid Malignancies
  • FIGURE 10.1: Number of CAR-T Cell Patents, 2013-2018
  • FIGURE 10.2: Major CAR-T Patent Applicants
  • FIGURE 11.1: Licensing, Joint Venture and Research Only Oncology Deals from 2013-2017
  • FIGURE 12.1: Number of Initiated CAR-T Cell Therapy Clinical Trials, 2007-2017
  • FIGURE 12.2: Percentage (%) of Total CAR-T Clinical Trials by Target
  • FIGURE 12.3: Research Focus on CAR-T Trials by Indication
  • FIGURE 12.4: A Model Showing Engineered CD19-CAR-T Cell Targeting CD19 Antigen on the Malignant Cell
  • FIGURE 12.5: CAR-T Cells Targeting Solid Tumor Antigen
  • FIGURE 12.6: CAR-T Therapy Pipeline Distribution by Indication
  • FIGURE 12.7: CAR-T Therapy Pipeline Distribution by Target Antigen
  • FIGURE 17.1: Global Market for CAR-T Cell Therapies, 2018-2023
  • FIGURE 17.2: Global Market for CAR-T Therapy by Geography, 2024
  • FIGURE 17.3: Global Market for CAR-T Therapy by Country, 2024
  • FIGURE 17.4: Global Market for CAR-T Cell Therapies by Targeted Antigen, 2018
Back to Top